USFDA approves Pfizer's Hympavzi for rare bleeding disorder hemophilia
Analysts expect sales of Hympavzi to reach $300 million by 2030, according to estimates compiled by LSEG. (Photo: Reuters) 2 min read Last Updated : Oct 11 2024 | 11:42 PM IST The U.S.…
